

Varifarma signs an exclusive distribution and license agreement with EUSA Pharma for QARZIBA® in Argentina.

Buenos Aires (Argentina) February 1st, 2022 – Laboratorio Varifarma SA, a company focused on complex therapies and orphan diseases, and devoted to increasing the life expectancy of the patient announce they have signed an exclusive distribution and licensing agreement for QARZIBA® in Argentina with EUSA Pharma (UK) Ltd., a global biopharmaceutical based in Hemel Hempstead, committed to transforming the lives of people affected by cancer or rare disease, globally.

QARZIBA® is a cancer medicine used to treat neuroblastoma, a cancer of nerve cells, in patients over 1 year of age. It is used in 2 groups of patients who have high-risk neuroblastoma (which has a high chance of coming back): patients who have had some improvement with previous treatments, which included blood stem-cell transplantation and patients whose neuroblastoma has not improved with other cancer treatments or has come back. Because the number of patients with neuroblastoma is low, the disease is considered ‘rare’, and QARZIBA® was designated an ‘orphan medicine’ on November 2012.

For medical information please visit: <https://eusapharma.com/contact/medical-information>

Lic. Marcelo Conti, Laboratorio Varifarma Director, commented: “A few years ago, at Varifarma we set out to bridge the gap between Argentine rare disease patients with unsatisfied needs and their access to innovative and effective therapies; QARZIBA® is one more step in that direction. We are very proud to receive this license and the confidence of EUSA Pharma that our team will work deeply committed to fulfill their expectations”.

About Varifarma

Focused on complex therapies and orphan diseases, Varifarma is a company which is devoted to increasing the life expectancy of the patient. Is our continuous commitment with innovation and the search of new effective therapies what has placed us as market reference in the oncology, hematology, hemophilia, transplant, and rare diseases divisions. We are renowned for our product’s high quality and our sustained commitment with the medical and scientific community. For over two decades, we have counted on distinguished professionals who have actively contributed to the

search for the best solutions for patients, as well as for new challenges. Our mission inspires a strategy focused on moving towards new therapies, consolidating a portfolio of cutting-edge medicines.

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in other select markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com.

On 16 March 2022, EUSA Pharma (UK) Ltd. was acquired by Recordati, an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. More information can be found in the press release [here](#).

For more information:

Varifarma

Luciana Conti
Group Head of Communication
Buenos Aires, Argentina
Tel: (54 11) 4723-2830
lconti@varifarma.com.ar

For more information, please visit www.varifarma.com and follow us on [Linkedin](#).

EUSA Pharma

EUSA Media
Rebecca Kerr
+44 7909 703627
media@eusapharma.com